Skip to main content

Madrigal Pharmaceuticals, Inc.

MDGL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001157601

In the last 90 days, Madrigal Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 3 sales; 414 institutions reported holding it in 13F filings for Q2 2026, worth $12.7B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Madrigal Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
3 filings
2 insiders, $7.95M in total
Insiders trading
2
Net value
−$7.95M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Madrigal Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Madrigal Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Sibold William JohnPresident and CEO197,746Sep 11, 20265
Kelley Shannon TGeneral Counsel11,474Aug 20, 20263
Reed John CDirector647Aug 18, 20261
Baker JulianDirector1,948,876IndirectJun 18, 20261
Baker FelixDirector1,948,876IndirectJun 18, 20261
Baker Bros. Advisors LPDirector1,948,876IndirectJun 18, 20261
Baker Brothers Life Sciences LPDirector1,948,876IndirectJun 18, 20261
667, L.P.Director1,948,876IndirectJun 18, 20261
Baker Bros. Advisors (GP) LLCDirector1,948,876IndirectJun 18, 20261
Fouse Jacqualyn ADirector1,551Jun 18, 20261
Taub RebeccaDirector452,667Jun 18, 20267
Levy Richard SDirector22,469Jun 18, 20265
Daly James MDirector3,081Jun 18, 20261
Brennan Daniel J.Director1,371Jun 18, 20261
Soergel DavidChief Medical Officer10,033Jun 1, 20263
Dier MardiEVP and CFO12,490Mar 6, 20263
Huntsman CaroleChief Commercial Officer12,692Mar 6, 20263
Thakkar RitaChief Accounting Officer2,398Jan 20, 20261
Friedman Paul ADirector187,164Jan 13, 20263
Bate KennethDirector2,627Nov 7, 20251
Craves Fred BDirector350,076Mar 14, 20250
Waltermire Robert E.Senior VP, Chief Pharma Dev.5,789Mar 7, 20250
Lynch Brian JosephSVP and General Counsel17,691Jan 25, 20240
Howarth Alex G.Chief Financial Officer18,737Jan 25, 20240
Sukhija RemyChief Commercial Officer15,001Jan 18, 20230
Milligan David VDirector–Jun 21, 20220
Gollust Keith RDirector–Jun 21, 20220
Bay City Capital LLC10% Owner1,261Dec 7, 20210
Bay City Capital Fund IV Co Invesment Fund LP10% Owner1,261Dec 7, 20210
Bay City Capital Management IV LLC10% Owner1,261Dec 7, 20210
Bay City Capital Fund IV, L.P.10% Owner1,261Dec 7, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 28, 2022 (view filing)Dec 235 daysSukhija RemyChief Commercial OfficerSSale−30.0K$274.14−$8.22M−100.0%0 after18 lots
Dec 28, 2022 (view filing)Dec 235 daysLynch Brian JosephSVP and General CounselSSale−7.00K$274.18−$1.92M−100.0%0 after14 lots
Jan 6, 2023 (view filing)Jan 33 daysLateLynch Brian JosephSVP and General CounselSSale−13.0K$282.92−$3.68M−100.0%0 after10 lots
Jan 19, 2023 (view filing)Jan 172 daysLevy Richard SDirectorSSale−22.5K$293.15−$6.59M−71.2%9.10K after10 lots
Mar 2, 2023 (view filing)Feb 28-Mar 12 daysWaltermire Robert E.Senior VP, Chief Pharma Dev.SSale−10.0K$273.24−$2.73M−63.8%5.67K after6 lots
Oct 5, 2023 (view filing)4:27 PM ETOct 32 daysBaker Julian and 5 othersDirectorPPurchase+1.65M$151.69+$250.0M–1.52M afterDerivative2 lots
Nov 15, 2023 (view filing)5:12 PM ETNov 13-142 daysBaker Julian and 5 othersDirectorPPurchase+107.5K$146.99+$15.8M+7.7%1.50M after30 lots
Nov 15, 2023 (view filing)5:13 PM ETNov 14-151 dayBaker Julian and 5 othersDirectorPPurchase+49.4K$158.13+$7.81M+3.3%1.55M after4 lots
Nov 21, 2023 (view filing)6:14 PM ETNov 17-204 daysBaker Julian and 5 othersDirectorPPurchase+67.1K$178.11+$11.9M+4.4%1.61M after30 lots
Nov 21, 2023 (view filing)6:15 PM ETNov 21Same dayBaker Julian and 5 othersDirectorPPurchase+64.3K$188.47+$12.1M+4.0%1.67M after20 lots
Dec 1, 2023 (view filing)Nov 29-302 daysLynch Brian JosephSVP and General CounselSSale−7.00K$201.50−$1.41M−31.8%15.0K after5 lots
Dec 6, 2023 (view filing)Dec 4-52 daysLynch Brian JosephSVP and General CounselSSale−2.80K$221.89−$621.3K−15.7%15.0K after3 lots
Dec 14, 2023 (view filing)Dec 12-132 daysWaltermire Robert E.Senior VP, Chief Pharma Dev.SSale−3.80K$222.82−$846.7K−40.1%5.67K after4 lots
Dec 14, 2023 (view filing)6:09 PM ETDec 122 daysBaker Julian and 5 othersDirectorPPurchase+34.6K$218.31+$7.55M+2.1%1.70M after30 lots
Dec 14, 2023 (view filing)6:10 PM ETDec 13-141 dayBaker Julian and 5 othersDirectorPPurchase+101.8K$221.20+$22.5M+6.0%1.79M after24 lots
Dec 18, 2023 (view filing)Dec 14-154 daysWaltermire Robert E.Senior VP, Chief Pharma Dev.SSale−4.00K$235.50−$942.0K−41.4%5.67K after4 lots
Mar 25, 2024 (view filing)Mar 214 daysBaker Bros. Advisors LPDirectorPPurchase+1.06M$260.00+$275.0M–2.49M afterDerivative2 lots
Apr 3, 2024 (view filing)Apr 1-22 daysDaly James MDirectorSSale−32.5K$252.97−$8.22M−96.4%1.20K after16 lots10b5-1
Apr 3, 2024 (view filing)Apr 1-22 daysBate KennethDirectorSSale−32.5K$252.86−$8.22M−96.4%1.20K after17 lots10b5-1
Apr 3, 2024 (view filing)Apr 12 daysLevy Richard SDirectorSSale−11.0K$257.48−$2.83M−51.6%10.3K after6 lots10b5-1
Apr 5, 2024 (view filing)Apr 3-52 daysFriedman Paul ADirectorSSale−73.7K$243.93−$18.0M−28.4%185.7K after20 lots10b5-1
Apr 5, 2024 (view filing)Apr 3-52 daysTaub RebeccaPres., R&D, and CMOSSale−73.9K$243.92−$18.0M−13.9%459.0K after19 lots10b5-1
Apr 10, 2024 (view filing)Apr 82 daysFriedman Paul ADirectorSSale−26.3K$246.19−$6.47M−12.4%185.7K after7 lots10b5-1
Apr 10, 2024 (view filing)Apr 82 daysTaub RebeccaPres., R&D, and CMOSSale−2.68K$245.99−$658.3K−0.6%459.0K after6 lots10b5-1
May 16, 2024 (view filing)May 142 daysCraves Fred BDirectorSSale−22.5K$212.87−$4.79M−5.2%413.4K after10 lots10b5-1
May 23, 2024 (view filing)May 212 daysWaltermire Robert E.Senior VP, Chief Pharma Dev.SSale−1.04K$231.34−$239.7K−15.9%5.50K after
Jun 14, 2024 (view filing)Jun 122 daysWaltermire Robert E.Senior VP, Chief Pharma Dev.SSale−2.00K$285.00−$570.0K−26.7%5.50K after
Jun 18, 2024 (view filing)Jun 144 daysWaltermire Robert E.Senior VP, Chief Pharma Dev.SSale−1.90K$280.00−$532.0K−25.7%5.50K after
Sep 11, 2024 (view filing)Sep 92 daysSibold William JohnPresident and CEOSSale−6.36K$243.83−$1.55M−10.2%55.9K after
Nov 5, 2024 (view filing)Nov 14 daysLevy Richard SDirectorSSale−5.00K$300.94−$1.50M−31.2%11.0K after4 lots10b5-1
Nov 8, 2024 (view filing)Nov 71 dayLevy Richard SDirectorSSale−5.00K$350.00−$1.75M−31.2%11.0K after10b5-1
Nov 22, 2024 (view filing)Nov 211 dayHuntsman CaroleChief Commercial OfficerSSale−688$316.92−$218.0K−6.0%10.8K after
Nov 27, 2024 (view filing)Nov 252 daysCraves Fred BDirectorSSale−3.40K$350.30−$1.19M−18.9%14.6K after2 lots
Dec 5, 2024 (view filing)Dec 32 daysCraves Fred BDirectorSSale−3.60K$315.31−$1.14M−24.7%11.0K after2 lots
Jan 17, 2025 (view filing)Jan 17Same dayTaub RebeccaPres., R&D, and CMOSSale−1.69K$273.41−$461.8K−0.4%457.3K after
Jan 17, 2025 (view filing)Jan 17Same dayWaltermire Robert E.Senior VP, Chief Pharma Dev.SSale−442$273.41−$120.8K−8.0%5.06K after
Jan 17, 2025 (view filing)Jan 17Same dayKelley Shannon TGeneral CounselSSale−277$273.41−$75.7K−3.5%7.71K after
Jan 27, 2025 (view filing)Jan 243 daysWaltermire Robert E.Senior VP, Chief Pharma Dev.SSale−103$335.24−$34.5K−2.0%4.96K after
Jan 27, 2025 (view filing)Jan 243 daysTaub RebeccaPres., R&D, and CMOSSale−648$335.24−$217.2K−0.1%456.7K after
Jan 27, 2025 (view filing)Jan 243 daysSibold William JohnPresident and CEOSSale−1.58K$335.24−$531.0K−2.8%54.3K after
Jan 27, 2025 (view filing)Jan 243 daysHuntsman CaroleChief Commercial OfficerSSale−347$335.24−$116.3K−3.2%10.4K after
Feb 28, 2025 (view filing)Feb 271 dayBate KennethDirectorSSale−20.0K$356.44−$7.13M−91.3%1.91K after9 lots
Feb 28, 2025 (view filing)Feb 271 dayDaly James MDirectorSSale−15.5K$347.45−$5.38M−89.0%1.91K after3 lots
Mar 4, 2025 (view filing)Feb 284 daysWaltermire Robert E.Senior VP, Chief Pharma Dev.SSale−1.23K$341.07−$418.5K−24.8%3.73K after2 lots
Mar 5, 2025 (view filing)Mar 32 daysHuntsman CaroleChief Commercial OfficerSSale−1.83K$325.98−$597.8K−17.6%8.60K after9 lots10b5-1
Mar 5, 2025 (view filing)Mar 32 daysDier MardiSVP and CFOSSale−1.96K$324.96−$637.3K−22.1%6.91K after2 lots10b5-1
Mar 5, 2025 (view filing)Mar 32 daysKelley Shannon TGeneral CounselSSale−415$335.00−$139.0K−5.4%7.29K after10b5-1
Mar 7, 2025 (view filing)Mar 52 daysWaltermire Robert E.Senior VP, Chief Pharma Dev.SSale−14.1K$341.33−$4.82M−79.1%3.73K after9 lots
Mar 12, 2025 (view filing)Mar 102 daysDier MardiSVP and CFOSSale−258$323.04−$83.3K−2.4%10.4K after10b5-1
Mar 14, 2025 (view filing)Mar 12-132 daysCraves Fred BDirectorSSale−15.5K$328.54−$5.08M−4.2%350.1K after13 lots